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The expression of the E6 protein from certain members of the HPV genus β (β HPV 5 and 8 E6) can disrupt
p53 signaling by diminishing the steady state levels of two p53 modifying enzymes, ATR and p300. Here,
we show that β-HPV 5 and 8 E6 are also capable of reducing the steady state levels of another p53
modifying enzyme, ATM, and as a result restrict LINE-1 retrotransposition. Furthermore, we show that
the reduction of both ATM and LINE-1 retrotransposition is dependent upon the ability of β-HPV 8 E6 to
bind and degrade p300. We use inhibitors and dominant negative mutants to conﬁrm that ATM is
needed for efﬁcient LINE-1 retrotransposition. Furthermore, neither sensitivity to LINE-1 expression nor
LINE-1 induced DSB formation is altered in an ATM deﬁcient background. Together, these data illustrate
the broad impact some β-HPVs have on DNA damage signaling by promoting p300 degradation.
& 2013 Elsevier Inc. All rights reserved.Introduction
Human Papillomaviruses (HPVs) are a family of small double
stranded DNA viruses that infect the mucosal and cutaneous epithe-
lia of humans. Infections with these viruses can result in a wide array
of clinical manifestations, ranging from inapparent infections to
anogenital carcinomas (Stanley, 2012). This large family contains
over 100 different HPV types and is divided based on DNA sequence
homology into ﬁve genera (Bernard et al., 2010). Of these genera, the
alpha genus (α-HPVs) has been most thoroughly characterized. The
α-HPVs can be subdivided based on the relative likelihood that a viral
infection will result in the development of a carcinoma. Infections by
low risk (LR) α-HPVs (including HPV 6 and 11) are most commonly
associated with genital warts and non-cancerous papillomas, while
high risk (HR) α-HPVs (including HPV 16, 18, 31, and 33) are the
causative agents in cervical cancers as well as other anogenital
cancers and in a subset of head and neck cancers (zur Hausen,
1999; Cogliano et al., 2005; Lorincz et al., 1992).
Members of the beta HPV genus (β-HPVs) may be associated
with the development of non-melanoma skin cancers (NMSC)
(Bouwes Bavinck et al., 2001; Pﬁster, 1992; Orth et al., 1979;ll rights reserved.
y).Lutzner et al., 1984; Akgul et al., 2006). The link between β-HPVs
and skin cancer was ﬁrst observed in patients with the rare genetic
disorder epidermodysplasia verruciformis (EV) (Pﬁster, 1992). EV
patients have a predisposition to the early development of
premalignant skin lesions, most of which occur in sun exposed
areas. DNA from these lesions was found to harbor β-HPV
genomes, including HPV 5 and 8 (Pﬁster, 1992). However, unlike
HR α-HPVs, β HPVs do not seem to be necessary for tumor
maintenance, suggesting that infection with these viruses may
act as a co-factor, enhancing the carcinogenic potential of ultra-
violet light (UV) exposure (Pﬁster, 1992; Nindl et al., 2007).
Nearly all HPVs express eight genes. Of these eight genes, E6 and
E7 are the primary viral oncogenes in HR α-HPVs (Galloway et al.,
2009; McLaughlin-Drubin and Munger, 2009). The HPV E6 proteins
are well characterized; particularly those expressed by high risk α-
HPV. High risk α-HPV E6 expression is capable of inducing a wide
variety of physiological changes in its host cell through an assortment
of interactions with host proteins (Lee et al., 2000, 1997; Kiyono
et al., 1997; Nakagawa and Huibregtse, 2000; Kuballa et al., 2007;
Thomas and Banks, 1999, 1998; Jing et al., 2007; Glaunsinger et al.,
2000). Characteristic of these interactions is the ability of HR α-HPV
E6 to target p53 for degradation by the proteasome via formation of a
complex with p53 and E6AP, a cellular E3 ubiquitin ligase
(Huibregtse et al., 1991; Scheffner et al., 1993, 1990). This results in
the abrogation of many cellular functions, including DNA damage
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et al., 1994).
In addition to disrupting DNA damage repair, the degradation
of p53 by high risk α-HPV E6 has been shown to abrogate the
mobilization of the retrotransposon, Long INterspersed Element-1
(LINE-1) (Haoudi et al., 2004). Numerous copies of LINE-1 ele-
ments are found throughout the genome, in total roughly 17% of
the entire genome is comprised of LINE-1 elements (Lander et al.,
2001). It is mobilized through a “copy and paste” mechanism,
known as retrotransposition, where LINE-1 DNA from one geno-
mic location is “copied” and “pasted” into a new genomic location.
Analysis of genomic LINE-1 inserts and of the Bombyx mori R2
element has led to a model for LINE-1 retrotransposition termed
target primed reverse transcription (TPRT) (Ostertag and Kazazian,
2001; Jurka, 1997; Luan et al., 1993; Luan and Eickbush, 1995).
TPRT predicts the generation of a double strand break (DSB) in the
genomic DNA followed by the insertion of a new copy of the
element into the lesion (Zingler et al., 2005; Voliva et al., 1984).
Indeed, this prediction is supported through immunostaining of
phosphorylated H2AX and 53bp1 foci as well as COMET assays that
demonstrate LINE-1 expression leads to high rates of DSBs in
tissue culture (Gasior et al., 2006; Wallace et al., 2010).
Because LINE-1 retrotransposition involves a DSB intermediate, it
is not surprising that the process is highly inﬂuenced by DNA repair
machinery (Gasior et al., 2006, 2008; Wallace et al., 2010). Some
repair proteins such as the ERCC1/XPF heterodimer, a ﬂap endonu-
clease, limit LINE-1 retrotransposition. Others like Ataxia telangiec-
tasia mutated (ATM), a PI3 kinase family member, seems to be
required for efﬁcient retrotransposition as cell deﬁcient for ATMwere
found to poorly support retrotransposition (Gasior et al., 2006, 2008).
p53 may also be involved in LINE-1 retrotransposition. Evidence for
an indirect role for p53 in LINE-1 retrotransposition was seen in cellsFig. 1. Beta HPV E6 expression decreases steady state ATM levels: (A) Representative i
HPV 16 E6 expression. Unlike β HPV E6 expression, HPV 16 E6 expression promotes
(B) Densitometry of immunoblots (n¼3) of ATM protein level in HPV E6 expressing HFK
ATM protein levels in LXSN cells arbitrarily set to 100. Error bars represent standard error
Student T test and 2 way ANOVA with Bonferroni correction). (C) Representative immun
ATM protein levels in HPV E6 HFK cells. Levels were normalized to β-actin for each exper
bars represent standard errors of the mean. * denotes a statistically signiﬁcant differ
correction).expressing high risk α-HPV E6 (Haoudi et al., 2004). Diminished
LINE-1 retrotransposition in these cells was linked to increased
sensitivity to LINE-1 expression resulting from high risk α-HPV E6
induced p53 reduction (Haoudi et al., 2004).
The ability to disrupt p53 dependent DNA damage repair is not
exclusive to high risk α-HPV E6. The expression of β-HPV 5 and 8 E6 is
also able to disrupt p53 mediated repair of UVB damaged DNA
(Giampieri and Storey, 2004). However, unlike high risk α-HPV E6,
β-HPV E6 expression is not capable of degrading p53 but instead
reduces the levels of two proteins, Ataxia Telangietcasia Mutated and
Rad3 Related (ATR) and p300, that modify p53 in response to UVB
induced DNA damage (Howie et al., 2011; Wallace et al., 2012).
Following UV damage, ATR and p300 phosphorylate and acetylate
p53, respectively (Sakaguchi et al., 1998; Gu and Roeder, 1997; Tibbetts
et al., 1999). Together these modiﬁcations, allow p53 to drive target
gene transcription in order to repair UV damaged DNA (Sakaguchi
et al., 1998; Tibbetts et al., 1999; Haupt et al., 1997; Kastan et al., 1991;
Maltzman and Czyzyk, 1984; Dohoney et al., 2004; Shieh et al., 1997).
In this work, we demonstrate that the expression of β-HPV
5 and 8 E6 expression is capable of reducing ATM protein levels
and that this reduction is dependent on the ability of the β-HPV E6
protein to bind p300 and promote its degradation. Additionally,
we show that not only does β-HPV E6 expression reduce LINE-1
retrotransposition in a manner that correlates with its ability to
reduce ATM levels, but also that it does not increase LINE-1
associated toxicity. Furthermore, we demonstrate, using both
chemical inhibitors and the exogenous expression of kinase dead
ATM protein, that ATM kinase activity is required for efﬁcient
LINE-1 retrotransposition. Finally, we demonstrate despite
reduced retrotransposition in cells lacking ATM, LINE-1 remains
capable of acting as an endogenous mutagen by inducing DSB
formation.mmunoblot showing ATM protein levels in HFK cells. p53 is shown as a control for
constitutive p53 degradation. Nucleolin (Nuc) was included as a loading control.
cells. Levels were normalized to nucleolin for each experiment and graphed with
s of the mean. * denotes a statistically signiﬁcant difference from LXSN cells (p≤0.05,
oblot showing ATM levels in HFK cells. D. Densitometer of immunoblots (n¼3) of
iment and graphed with ATM protein levels in LXSN cells arbitrarily set to 100. Error
ence from LXSN cells (p≤0.05, Student T test and 2 way ANOVA with Bonferroni
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β HPV E6 expression diminishes ATM levels by promoting p300
degradation
We have previously shown that β-HPV 5 and 8 E6 expression
can reduce the steady-state protein levels of one PI3 kinase family
member, ATR (Wallace et al., 2012). To determine if β-HPV E6
expression could also attenuate steady-state protein levels of the
related PI3 kinase family member ATM, we expressed three β-HPV
E6 (HPV 5, 8, and 38 E6) and one high risk α-HPV E6 (HPV 16 E6)
in human foreskin keratinocytes (HFK). A dearth of antibodies to
β-HPV E6 proteins makes it impossible to determine their protein
expression, but their relative expression was conﬁrmed using semi
quantitative RT-PCR (Supplemental Fig. 1). Additionally, as a
control, we generated vector (LXSN) only HFK cells. We measured
ATM protein levels by immunoblot and found ATM levels to be
signiﬁcantly reduced in HFK cells expressing β HPV 5 and 8 E6
(Fig. 1A and B; p≤0.05). In contrast, expression of either HPV 38 or
16 E6 did not result in a signiﬁcant decrease in ATM levels (Fig. 1A
and B). To determine if this reduction in ATM protein levels results
in an attenuated ATM activation in response to DNA damage, we
measured phospho-Chk2 levels by immunoblots following DNA
damage. In untreated cells, phospho-Chk2 levels were unaltered
by β-HPV E6 expression. However, following DNA damage, β-HPV
5 and 8 E6 expressing cells had diminished phospho-Chk2 levels.
As with ATM protein levels, phospho Chk2 levels were similar to
control levels in HPV 38 E6 expressing cells (Supplemental Fig. 2).
Because the HPV 8 E6 mediated reduction of ATR is dependent
on the ability of HPV 8 E6 to bind and promote the degradation ofFig. 2. Beta HPV E6 expression reduces steady state ATM levels by promoting p30
cotransfected with either p300wt or p300 S1834E and vector control or HPV 8 E6. β-Ac
protein levels in HPV E6 expressing HFK cells cotransfected with either p300wt or p300
experiment and graphed with p300wt arbitrarily set to 100. Error bars represent standa
cotransfected with vector control and p300wt (p≤0.05, Student T test). (C) p300 was kno
pool of 4 non-targeting siRNAs. Representative immunoblots showing ATM and p300 le
(D) Densitometry of immunoblots (n¼3) of ATM and p300 protein levels in HFK cells tr
siRNAs. Levels were normalized to β-actin for each experiment and graphed with contr
denotes a statistically signiﬁcant difference from HFK cells transfected with control siRNp300 (Wallace et al., 2012), we hypothesized that the reduction of
ATM protein levels would be similarly dependent on the ability of
HPV 8 E6 to promote p300 degradation. To test this hypothesis, we
expressed a previously described deletion mutant of HPV 8 E6 that
lacks the residues responsible for p300 binding and degradation
(HPV Δ8 E6) in HFK cells (Howie et al., 2011; Muller-Schiffmann
et al., 2006). Next, we conﬁrmed the expression of HPV Δ8 E6 in
HFK cells using semi quantitative RT-PCR (Supplemental Fig. 1). In
support of our hypothesis, the mutated HPV 8 E6 lost the ability to
reduce ATM levels (Fig. 1C and D) along with its ability to reduce
p300 levels (Howie et al., 2011).
To provide more speciﬁc evidence that the effect of HPV 5
and 8 E6 on ATM is mediated by promoting p300 degradation, we
co-transfected HFK cells with either a vector control or HPV 8 E6 in
combination with either a wild-type or a phosphomimetic p300
mutant (p300 S1834E) that has previously been shown to be
resistant to HPV 8 E6 mediated degradation (Howie et al., 2011).
ATM levels in HFK cells were unchanged by the co-transfection of
either p300 plasmid along with the vector control (Fig. 2A and B).
However, while ATM levels were signiﬁcantly reduced in cells
co-transfected with wild-type p300 and HPV 8 E6 (p≤0.05), ATM
levels remained unperturbed in cells co-transfected with HPV 8 E6
and the phosphomimetic p300 mutant (Fig. 2A and B). Furthermore,
depletion of p300 by siRNA results in an approximately 50% reduc-
tion in ATM levels compared to a control siRNA (Fig. 2C and D).
LINE-1 retrotranspostion requires ATM kinase activity
The dependency of LINE-1 retrotransposition on ATM has
previously been implicated based on cells derived from Ataxia0 degradation: (A) Representative immunoblot showing ATM levels in HFK cells
tin was used as a loading control. (B) Densitometry of immunoblots (n¼3) of ATM
S1834E and vector control or HPV 8 E6. Levels were normalized to β-actin for each
rd errors of the mean. * denotes a statistically signiﬁcant difference from HFK cells
cked down in HFK cells by transfection with a pool of 4 siRNAs targeting p300 or a
vels in these HFK cells 72 h post transfection. β-actin was used as a loading control.
ansfected with a pool of four p300 targeting siRNAs or a pool of four non targeting
ol siRNA arbitrarily set to 100. Error bars represent standard errors of the mean. *
As (p≤0.05, Student T test).
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2006). ATM is a PI3 kinase family member with the ability to
phosphorylate a wide array of targets in response to DNA damage
and to activate cell-cycle arrest in response to ionizing radiation
(Cortez et al., 1999; Matsuoka et al., 2000; Geng et al., 2007; Lim
et al., 2000; Taniguchi et al., 2002; Sarkaria et al., 1999). Consistent
with a role for ATM in DNA damage repair, ATM deﬁcient cells
demonstrate increased sensitivity to ionizing radiation (Elkind,
1984; Kuhne et al., 2004; Taylor et al., 1975). Because of the role
ATM plays in DNA damage repair and the genomic instability
characteristic of AT patients (Leonard et al., 2004), the use of
isogenic cell lines derived from AT patients may be complicated by
secondary mutations that disrupt the expression of a protein
critical for LINE-1 mobilization other than ATM (Meyn, 1993). As
a result, the previously reported abrogation of LINE-1 retrotran-
sposition may be an indirect result of ATM loss or other effects on
LINE-1 expression/activity in these cell lines.
To conﬁrm that ATM kinase activity is directly required for
LINE-1 retrotransposition, we determined how ATM kinase inhi-
bitors affect LINE-1 retrotransposition in HeLa cells. Retrotranspo-
sition of a tagged LINE-1 (LINE-1 neoR) (Moran et al., 1996) was
measured as described in Fig. 3A in the presence of PI3 kinase
inhibitors (caffeine (Sarkaria et al., 1999), wortmannin (Sarkaria
et al., 1998), and vanillin (Durant and Karran, 2003)). This tagged
LINE-1 confers neomycin resistance to cells following a retro-
transposition event. Additionally, as a control for toxicity and
colony formation, cells were transfected in parallel with an
unrelated neomycin-resistance (NeoR) expression plasmid as
described in Fig. 3B. In vitro and in vivo analyses of kinase activity
have demonstrated that caffeine inhibits ATM and ATR, but not
DNAPKcs at 5 mM (Sarkaria et al., 1999). LINE-1 retrotransposition
was reduced to 2% of DMSO control levels in the presence of 5 mM
caffeine (Fig. 3C). Treatment with 5 mM caffeine had no effect on
NeoR colony formation (Fig. 3C). Wortmannin inhibits ATM and
DNAPKcs, but not ATR at 4 μm in vitro and in vivo (Sarkaria et al.,
1998). Colony formation in cells transfected with NeoR plasmid
was not reduced at a concentration of 4 μMwortmannin, but there
was a signiﬁcant attenuation of LINE-1 retrotransposition at the
same concentration (Fig. 3C; p≤0.05). Because the wortmannin
was desolved in DMSO, we needed to conﬁrmed that the reduction
in retrotransposition was speciﬁc to the inhibitor and not a result
of the solvent. To test this we measured NeoR colony formation in
cells grown in DMSO corresponding to the amount of DMSO
needed to expose cells to 4 μM of wortmannin. Despite some
decreased NeoR colony formation, retrotransposition levels were
not reduced by DMSO (Fig. 3C). Vanillin acts as an inhibitor of
DNAPKcs but not ATM or ATR at 1 mM concentration in vivo
(Durant and Karran, 2003). While 1 mM Vanillin was able to
reduce LINE-1 retrotransposition, it also similarly reduced NeoR
colony formation, suggesting that the effect is non-speciﬁc toxi-
city/colony formation disruption (Fig. 3C). Given that the common
target of wortmannin and caffeine is ATM, these results support
the hypothesis that ATM kinase activity is necessary for LINE-1
retrotransposition.
To further implicate ATM kinase activity as speciﬁcally impor-
tant for LINE-1 retrotransposition, we co-transfected cells with
LINE-1 neoR and either wild type ATM or a kinase dead mutant of
ATM (ATMkd) that is capable of inhibiting ATM activity through a
dominant negative mechanism (Morgan et al., 1997). This domi-
nant negative fragment of ATM is well characterized and its
expression results in the speciﬁc inhibition of ATM activity
(Morgan et al., 1997; Kastan and Lim, 2000; Kastan et al., 2000)).
Indeed, the expression of the ATM kinase dead dominant negative
phenocopies ATM deﬁciency, resulting in the loss of cell cycle
arrest in response to IR, hypersensitivity to IR, failure to stabilize
p53 in response to DNA damage, and increased chromosomefragility (Morgan et al., 1997; Tang et al., 2008; Yamamoto et al.,
2012). Transfection with ATMkd reduced LINE-1 retrotransposition
to 50% of that observed in cells transfected with wild type ATM
(Fig. 3D). To assure that this reduction was not caused by non-
speciﬁc toxicity resulting from the inhibition of ATM activity by
ATMkd expression, we co-transfected NeoR with either wild type
ATM or ATMkd. NeoR colony formation was only minimally
affected by ATMkd expression (Fig. 3D). Additionally, it is unlikely
that over expression of ATM alone decreases LINE-1 retrotranspo-
sition as an N-terminal deletion of the wild type ATM construct
showed similar colony frequency as the intact ATM expression
construct (data not shown). Unfortunately, in our hands, the effect
of ATM knockdown by RNAi on LINE-1 retrotransposition could
not be accurately tested due to high levels of non-speciﬁc reduc-
tion in retrotransposition (Supplemental Fig. 3).
β HPV 5 and 8 E6 expression attenuates LINE-1 retrotransposition in a
manner that correlates with their reduction of steady state ATM levels
Because expression of HPV 5 and 8 E6 is capable of reducing the
steady state levels of ATM, and ATM kinase activity is required for
LINE-1 retrotransposition, we hypothesized that HPV 5 and 8 E6
expression would attenuate LINE-1 retrotransposition. It is tech-
nically difﬁcult to measure tagged retrotransposition in primary
cells, so we used previously characterized HPV 5, 8, 38, and 16 E6
expressing HT1080 cells (Howie et al., 2011; Wallace et al., 2012).
Because the plasmid expressing the HPV E6 proteins confers
neomycin resistance as its selectable marker, it is necessary to
use a tagged LINE-1 construct that confers blasticidin resistance
following retrotransposition (LINE-1 BlastR) in lieu of the LINE-1
NeoR construct. Therefore, to test our hypothesis that HPV 5 and
8 E6 expression results in diminished LINE-1 retrotransposition,
we transfected HPV E6 expressing HT1080 cells with LINE-1
BlastR. LINE-1 BlastR colony formation was reduced by more than
50% in HT1080 cells expressing HPV 5 and 8 E6, while retro-
transposition levels in HPV 38 E6 expressing cells were not
signiﬁcantly different from control (Fig. 4A; p≤0.05). Importantly,
as previously reported, HR α HPV E6 (HPV 16 E6) expression also
resulted in a signiﬁcant reduction in LINE-1 retrotransposition
(Fig. 4A; p≤0.05).
The deletion in HPV Δ8 E6 that abrogates its ability to promote
p300 degradation also renders the protein incapable of reducing
ATM levels. To determine if HPV Δ8 E6 also lost its ability to
attenuate LINE-1 retrotransposition, we measured LINE-1 retro-
transposition in HPV Δ8 E6 expressing HT1080 cells. Transfection
of LINE-1 BlastR into HPV Δ8 E6 expressing HT1080 cells resulted
in retrotransposition that was not signiﬁcantly different from the
control cells (Fig. 4B; p≤0.05).
ATM reduction does not sensitize cells to LINE-1 expression
We have shown that the previously described reduction in
LINE-1 retrotransposition (Gasior et al., 2006), in cells derived
from an AT patient, can be explained by a dependence of efﬁcient
LINE-1 retrotransposition on ATM and not secondary mutations
resulting from inadequate DNA damage repair. Having conﬁrmed
the importance of ATM in efﬁcient retrotransposition, we wished
to attempt to characterize the role ATM plays in retrotransposition.
One possibility is that ATM helps repair the damage associated
with LINE-1 expression and that loss of the protein would result in
increased sensitivity to LINE-1 expression. Speciﬁcally the double
strand break (DSB) induced by LINE-1 expression could be more
toxic in an ATM- background. To characterize LINE-1 toxicity in the
absence of ATM, we performed a LINE-1 toxicity assay in ATM null
and complement ﬁbroblast cells. In this assay, an untagged LINE-1
expressed from an episomal vector is co-transfected with a
Fig. 3. LINE-1 retrotransposition requires ATM kinases activity: (A) LINE-1 retrotransposition assay. A tagged full Length LINE-1 retrotransposon is transfected into cells.
This 3′ tag consists of a reporter (Blastocidin/Neomicin resistance) construct including promoter in the opposite orientation of the retrotransposon. A self-splicing intron in
the same orientation as the retrotransposon disrupts the reporter gene. Following transcription from the LINE-1 promoter, this intron is removed resulting in LINE-1 mRNA
that contains a reporter gene that is no longer disrupted by the intron. This mRNA is then reverse transcribed and inserted into the genome by target primed reverse
transcription (TPRT). The new LINE-1 insert also contains a now functional reporter gene that is capable of providing Neomycin/Blasticidin resistance to the cell containing
the new insertion. Resistant colonies resulting from the cells containing these inserts are scored as evidence of at least one LINE-1 retrotransposition event. (B) NeoR/BlastR
colony formation assay. In order to assess the impact of inhibitor treatment or exogenous gene expression on colony formation, cells transfected with a reporter plasmid are
either co-transfected with the exogenous gene of interest (an untagged LINE-1 or ATM) or treated with inhibitor. These cells are then grown in selection media and relative
colony formation is used as an indication of the impact inhibitor treatment/exogenous gene expression has on colony formation. (C) Caffeine, DMSO, wortmannin, and
vanillin were analyzed for effects on colony formation following transfection with a tagged LINE-1 (L1) expression vector or Neomycin resistance (NeoR) vector as a control.
HeLa were transfected with either LINE-1 NeoR or NeoR vectors and treated with the indicated ﬁnal concentrations of inhibitors or DMSO as a control. Selection media was
added 48 h post transfection. Charts show average number of colonies relative to untreated control that was arbitrarily set to 100. Error bars represent standard errors of the
mean. * Denotes signiﬁcant lower than NeoR control (p≤0.05 student T-test). (D) Tagged LINE-1 expression vector or Neomycin resistance vector were cotransfected with
ATM cDNA or ATM kinase defective (ATMkd) and colonies were quantiﬁed after growth for 2 weeks in selection media. Charts show mean (triplicate in four independent
experiments) number of colonies relative to ATM cDNA control that was arbitrarily set to 100. Error bars represent standard errors of the mean. * Denotes signiﬁcant lower
than NeoR control (p≤0.05 student T-test).
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formation is independent of LINE-1 retrotransposition. While
expression of LINE-1 reduces blasticidin colonies by over 40%
relative to control in ATM+ cells, LINE-1 toxicity is signiﬁcantly
less in ATM- cells (Fig. 5A; p≤0.05).
Similarly, the reduction in LINE-1 retrotransposition in HPV 5 and
8 E6 expressing cells may be the result of increased LINE-1 toxicity.
Not only is this the proposed mechanism contributing to decreased
LINE-1 retrotransposition in HR α HPV E6 expressing cells, but HPV
5 and 8 E6 expression has been shown to increase sensitivity to DNAdamaging agents (Haoudi et al., 2004; Wallace et al., 2012). For these
reasons, we tested the effect of HPV E6 expression on LINE-1 toxicity.
LINE-1 toxicity was evaluated in HPV E6 expressing cells using a
previously described cellular proliferation assay (Wallace et al.,
2008). In this assay, the effect of LINE-1 ORF2 expression on cellular
proliferation over a three day period was compared to an empty
vector control (pBud). As has been previously reported (Wallace et al.,
2008), LINE-1 ORF2 expression resulted in a signiﬁcant reduction in
cellular proliferation in control cells (Fig. 5B; p≤0.05). This toxicity
was not signiﬁcantly altered in HPV 5, 8, or 38 E6 expressing cells
Fig. 4. HPV E6 expression attenuates LINE-1 retrotransposition: (A) and
(B) Retrotransposition of a tagged LINE-1 (LINE-1 BlastR) was measured in HPV
E6 expressing HT1080 cells. The chart shows mean colony numbers (n¼4) relative
to LXSN control HT1080 cells. Error Bars represent standard errors of the mean.
* denotes statistically signiﬁcant difference from LXSN (p≤0.05, Student T test and
2 way ANOVA with Bonferroni correction).
Fig. 5. Decreased ATM levels do not sensitize cells to LINE-1 expression: (A) The
AT derived cell lines YZ-5 (ATM complemented) and EBS-7 (ATM-) were transfected
with LINE-1 expression vector (L1) or control vector (pCEP4) in combination with a
blasticidin resistance plasmid. Cells underwent selection for blasticidin for two
weeks and colonies were counted to measure LINE-1 toxicity. Error bars represent
standard errors of the mean. * denotes signiﬁcant difference from empty vector
control (p≤0.05, Student T test). 1 denotes signiﬁcantly different from YZ-5 cells.
(B) HPV E6 expressing HT1080 cells were transfected with either an empty vector
or one expressing LINE-1 ORF2. 24 h after transfection, growth media was replaced
with selection media and cells were grown for an additional three days. Chart
shows mean (n¼3) proliferation in LINE-1 ORF2 transfected cells relative to control
transfected cells. Error bars represent standard errors of the mean. * denote a
statistical difference from LINE-1 ORF2 transfected LXSN cells (p≤0.05, Student T
test and 2 way ANOVA with Bonferroni correction). 1 denotes a statistically
signiﬁcant difference from control transfected cells (p≤0.05, Student T test and
2-way ANOVA with Bonferroni correction).
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LINE-1 expression (Fig. 5B).
To better understand the role of ATM in LINE-1 retrotransposi-
tion, we explored the possibility that the lack of robust LINE-1
retrotransposition in the absence of ATM kinase activity might be
explained by a dependence on LINE-1 ORF2 endonuclease activity
on ATM. This might be the case if LINE-1 ORF2 was an ATM kinase
substrate. To determine whether LINE-1 ORF2 retained its endo-
nuclease capability in an ATM- context, a neutral COMET assay was
performed in YZ-5 (ATM+) and EBS-7 (ATM-) cell lines after
transfection with LINE-1 expression plasmids. A neutral COMET
assay is a single-cell gel electrophoresis based assay that measures
DSBs by looking for increased DNA mobility, or tail length, as a
result of the break. Twenty-four hours after transfection, LINE-1
expression increased the tail length of most of the population of
ATM+ and ATM- cells compared to cells transfected with an empty
vector. Further, to characterize the contribution of the LINE-1 ORF2
endonuclease domain in LINE-1 induced DSBs, we performed a
neutral COMET assay in cells transfected with vector expressing
LINE-1 containing a previously described mutation (L1 EN205A) in
its endonuclease domain (Feng et al., 1996). Interestingly, in both
ATM+ and ATM- cells, transfection with L1 EN205A demonstrated
an increase in fragmented DNA at a level intermediate between
empty vector and wild type LINE-1 (Fig. 6A and B). In both ATM+
and ATM- cells, LINE-1wt increased the tail moment roughly 60%
over empty control (Fig. 6A and B), while L1 EN205A expression
increased the tail moment by approximately 25% independently of
ATM status. Thus the lack of toxicity as well as LINE-1 retro-
transposition in ATM- cells was not due to a lack of LINE-1
expression or inability to induce DNA lesions.Discussion
The data described here provides a link between β HPV-E6
mediated repression of DNA damage repair signaling and the
retrotransposition of LINE-1 that is of interest to the ﬁelds of viral
oncology and retrotransposition. We have previously shown that
β HPV E6 expression can disrupt the repair of UVB induced DNA
damage by reducing the steady state levels of a PI3 kinase, ATR,
that plays a central role in the repair of UVB induced lesions
(Wallace et al., 2012). In this work, we demonstrate that HPV 5 and
8 E6, but not HPV 38 or 16 E6, expression can reduce steady state
levels of a related PI3 kinase, ATM, diminishing its activation in
response to DNA damage (Fig. 1A and B and Supplemental Fig. 2).
By introducing mutations into HPV 8 E6 as well as p300, we
establish that the ability to reduce ATM protein levels is depen-
dent on the capability of HPV 8 E6 to bind and promote p300
degradation (Fig. 1C and D, and 2). Furthermore, we use the
expression ATM dominant negative mutants as well as chemical
inhibition to show that ATM activity is required for efﬁcient LINE-1
retrotransposition (Fig. 3).
Additionally, we show that the reduction of LINE-1 retro-
transposition by increased sensitivity to LINE-1 ORF2 activity is
likely to be a conserved method of restricted retrotransposition in
high risk HPV E6 expressing cells (Fig. 5 and (Haoudi et al., 2004)).
Perhaps more interestingly, certain β-HPV E6 proteins can also
obstruct efﬁcient LINE-1 retrotransposition although through a
different mechanism (Fig. 4). Unlike high risk α-HPV E6
Fig. 6. LINE-1 induced DSB formation is not altered in ATM-/- cells: (A) YZ-5 (ATM complemented) and EBS (ATM-) cells were transfected with LINE-1 expression vectors,
either wild type or an endonuclease mutant (L1 EN205A), or a control empty vector. 24 h later the cells were harvested and subjected to neutral COMET assay. The relative
tail moment is shown for each cell. (B) Means of two replicates of neutral COMET assays. Tail length was set relative to empty vector control. Error Bars represent standard
errors of the mean. * denote statistical difference from vector control (p≤0.05, Student's T test).
N.A. Wallace et al. / Virology 443 (2013) 69–79 75expression, β-HPV 5 and 8 E6 expression does not limit retro-
transposition by increasing the toxicity of LINE-1 expression
(Fig. 5). Instead, the attenuation of LINE-1 retrotransposition by
β-HPV E6 proteins correlates with their ability to reduce ATM
protein levels (Figs. 1 and 4). This mechanism is supported by our
observation that LINE-1 associated toxicity is not reduced by ATM
complementation of ATM- cells (Fig. 5). Finally, using neutral
comet assays, we were able to determine that LINE-1 endonu-
clease activity is not dependent on ATM activity as LINE-1 expres-
sion induces similar levels of DSBs in both ATM+ and ATM- cells.
Together these data demonstrate not only an ever expanding
ability of β HPV E6 expression to attenuate the cellular response
to DNA damage, but also further characterize the impact of cellular
DNA damage machinery on LINE-1 retrotransposition.
There have been conﬂicting reports about the role of ATM in
LINE-1 retrotransposition (Gasior et al., 2006; Coufal et al., 2011).
While we have previously published that ATM is required for LINE-
1 retrotransposition in immortalized ATM-deﬁcient human ﬁbro-
blast, recent work by Coufal et al. (2011) shows a modest increase
in LINE-1 retrotransposition in various cells following ATM knock
out (ATM-KO) or depletion by shRNA. While both our current work
and the study by Coufal et al. demonstrate that LINE-1 retro-
transposition events can occur without ATM kinase activity, they
differ on the effect of ATM-KO on retrotransposition. In our hands,
LINE-1 retrotransposition is disrupted not only by RNAi mediated
knockdown of ATM, but also by the targeted knock down of
several extraneous proteins (Supplemental Fig. 3). Together, thesedata suggest that ATM depletion by RNAi is not ideal for this
studying ATM's impact on LINE-1 mobilization. Furthermore,
because LINE-1 retrotransposition is inﬂuenced both positively
and negatively by DNA repair proteins (Haoudi et al., 2004; Gasior
et al., 2006; Wallace et al., 2010; Gasior et al., 2008), the numerous
off target effect (ATR, p53, Mre11, and BRCA1) by the shRNA
knockdown of ATM in the Coufal et al. (2011) study make it
difﬁcult to interpret their observed increase in LINE-1 retrotran-
sposition. Conversely, our inhibition of ATM by expressing ATM
dominant negative mutants studies are likely less sensitive to off
target effect as none have been reported from these mutants.
Our data also demonstrates that, unlike optimal LINE-1 retro-
transposition, LINE-1 induced DSBs formation does not require ATM
(Fig. 6). This implies that LINE-1 elements remain active endogenous
mutagens in ATM-compromised individuals, such as Ataxia Telan-
giectasia (AT) patients and people infected with HPV 5 or 8. Indeed, if
the loss of ATM mediated DNA damage signaling results in proces-
sing of LINE-1 induced breaks by alternative/error-prone repair
pathways, LINE-1 activity could account for a portion of the genetic
instability of cells derived from AT patients. Similarly, our data
suggest that β-HPV infections may enhance the mutagenic potential
of LINE-1 expression by reducing steady state ATM protein levels in
infected cells. This could result in misrepair of LINE-1 induced DSBs
leading to mutations that are capable of continuing to drive
tumorigenesis after the infection is cleared.
Interestingly, in both the ATM complemented and ATM deﬁ-
cient cell lines, expression of LINE-1 containing a mutation in the
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DSBs intermediate between vector control and wild-type LINE-1
transfected cells (Fig. 6). This mutation has been shown to
abrogate most LINE-1 retrotransposition, but has been used to
characterize multiple endonuclease independent capabilities of
LINE-1. We speculate that these observations could be explained if
the mutant LINE-1 ORF2, while retaining some endonuclease
activity, as suggested by our data, is deﬁcient in another step in
retrotransposition or that the DSBs that it generates are no longer
capable of supporting LINE-1 retrotransposition, perhaps due to an
altered recognition site.
The impact of diminished steady state ATM levels in β-HPV
5 and 8 E6 expressing cells is not likely to be limited to matters
related to LINE-1 retrotransposition. We have previously shown
β-HPV 5 and 8 E6 mediated reduction of ATR expression allows
cells to continue replicating following UVB exposure (Wallace
et al., 2012). This allows the virus access to the cellular replication
machinery that would otherwise be restricted by G1 arrest. The
reduction of ATM protein levels may provide a similar advantage
to the virus. ATM and ATR are related PI3 kinases that phosphor-
ylate and stabilize p53 in response to DNA damage (Tibbetts et al.,
1999; Banin et al., 1998). Although they share a common target the
two kinases respond primarily to different types of DNA damage.
While ATR tends to respond to crosslinks in DNA (Tibbetts et al.,
1999), ATM is more responsive to DSBs (Banin et al., 1998). Thus
the β-HPV mediated reduction of ATM protein may provide
additional protection against DNA damage induced cell cycle
arrest, a protection that although beneﬁcial to the virus has the
potential to result in oncogenic mutations to cellular DNA.
Interestingly, despite the 495% depletion of p300 by RNAi,
ATM was only reduced by about 50%. These data can be explained
in at least two ways. ATM expression could be only partially
dependent on p300 expression. As p300, pCAF, and CBP can each
acetylate some of the same substrates, perhaps one of these
histone acetyltransferases also acts in an overlapping manner
with p300 to promote ATM expression (Liu et al., 1999; Tini
et al., 2002). Alternatively, ATM expression may be completely
dependent on p300, but only require a minute amount of p300 to
promote its expression. In this scenario, even with a 95% reduc-
tion, enough p300 might still be present for suboptimal ATM
expression.
In HPV infected cells, both E6 and E7 are expressed and often
have complementary roles in the viral lifecycle. Additionally, HR
HPV E7 is able to interact with ATM (Moody and Laimins, 2009).
Furthermore, HR HPV E7 interacts with the HAT, p300, whose
reduction by certain β-HPV E6 proteins leads to reduced steady
state ATM protein levels (Howie et al., 2011). As a result, β-HPV E7
expression has the potential to alter ATM activation or expression.
Moreover, to the best of our knowledge, neither the impact of HR
HPV E7, nor β-HPV E7 expression on LINE-1 retrotransposition has
been explored. We suggest that the relationships among HPV E7
proteins and LINE-1 retrotransposition, as well as the potential for
β-HPV E7 expression to affect ATM expression, are enticing areas
of future investigation.
One of the principle ways that HR α-HPVs manipulate the host
cellular environment to be more conducive to viral propagation is
by targeting the tumor suppressor p53 for proteasome degrada-
tion (Scheffner et al., 1990). By degrading p53, HR α-HPVs are able
to perturb numerous cellular pathways including DNA damage
repair and cell cycle arrest (Foster et al., 1994; Gu et al., 1994).
β-HPV 5 and 8 employ a more nuanced approach by reducing p53-
modifying proteins (ATM, ATR, and p300) and as a result more
subtly disrupting DNA damage repair and cell cycle arrest in
response to damage. We have previously shown that the degrada-
tion of p300 allows β-HPV 5 and 8 E6 expressing cells to blunt
differentiation as well as UVB induced cell cycle arrest byattenuating ATR activity (Wallace et al., 2012). Here we show that
p300 plays an even larger role in DNA repair than previously
reported as steady state ATM levels are signiﬁcantly diminished
when p300 is reduced by siRNA (Fig. 2C and D; p≤0.05) or HPV
5 and 8 E6 expression (Fig. 1; p≤0.05). This novel connection
between p300 and ATM protein levels expands our understanding,
not only of role p300 plays in DNA damage repair, but also of the
ways β-HPV 5 and 8 manipulate their host cell environment
through the destabilization of p300.Methods and materials
Tissue culture
HeLa cells (ATCC Manassas, VA) were cultured in EMEM media
plus non-essential amino acids and sodium pyruvate supplemen-
ted with 10% fetal bovine serum (Gibco/Invitrogen, Carlsbad, CA).
YZ-5 and EBS-7 cells were also maintained in the same media as
HeLa cells with the addition of hygromycin B at a concentration of
120 μg/ml to maintain episomal cATM and corresponding empty
vector. Wortmannin, caffeine, and vanillin were all purchased from
Sigma-Aldrich (St. Louis, MO) G418/Geneticin was added to a ﬁnal
concentration of 400 μg/ml for selection in colony formation
assays (Gibco/Invitrogen). Blasticidin S (Sigma-Aldrich) was used
at a concentration of 5 μg/ml for selection during colony formation
assays.
HT1080 cells are a spontaneously immortalized ﬁbrosarcoma
that contain a constitutively activate N-Ras gene. Primary human
foreskin keratinocytes (HFKs) were derived from neonatal human
foreskins and grown in EpiLife medium supplemented with
calcium chloride (60 μM), human keratinocyte growth supplement
(Cascade Biologics, Portland, OR) and penicillin-streptomycin.
Multiple derivations of HFK cells from neonatal human foreskins
were utilized in this work. Following viral transduction, and
selection, HPV E6 expression was conﬁrmed using semi quantita-
tive rt-PCR to measure HPV E6 levels. Functional assays were also
used to conﬁrm HPV E6 expression based on reported activities of
each viral protein. Immunoblot functionally conﬁrmed HPV 5 and
8 E6 expressing cells as cells had greatly diminished levels of p300
protein (Howie et al., 2011) and HPV 16 E6 expressing cells also
had dramatically less p53 protein (Scheffner et al., 1990). HT1080
and 293T cells were grown in DMEM medium supplemented with
10% Fetal Bovine Serum.
Transfections
Brieﬂy HPV E6 genes cloned into the LXSN vector (Miller and
Rosman, 1989) were co-transfected with VSV-G helper plasmids
into 293T cells using Fugene 6 (Roche), and retrovirus was
collected at 12, 24, 36, and 48 h post transfection. Transiently
produced virus was concentrated by ultracentrifugation and used
to infect HFK and HT1080 monolayers (50–60% conﬂuent) in the
presence of polybrene (8 μg/ml). Four hours after infection, cells
were washed with phosphate buffered saline (PBS pH¼?) and the
media replaced. The cells were expanded when conﬂuent and
placed under neomycin-G418 selection (50 mg/l) for 7 days. All
p300 transient transfections were done using TransIT Keratinocyte
transfection reagent (Mirus), and assessed 72 h later for steady
state levels of ATM. siRNA speciﬁc for p300 and controls were
purchased from Dharmacon RNA Technologies. siRNA transfec-
tions were done using RNAiMAX (Invitrogen) according to the
manufacturer's guidelines, and were assessed for steady state
p300 and ATM protein levels 72 h after transfection. shRNA
transfections were conducted using Lipofectamine with PLUS
reagent (Invitrogen), as speciﬁed by the manufacturer.
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mine with PLUS reagent for transfections as directed by the
manufacturer. For LINE-1 retrotransposition assays with inhibitors,
150,000 HeLa cells were seeded per T75 and transfected the next
day with 0.3 μg of LINE-1 NeoR or NeoR vector. Inhibitor treat-
ments were added at the end of the Lipofectamine transfection at
the indicated doses. The inhibitors were then refreshed the
following morning and early evening. Selection media was added
2 days post-transfection. For LINE-1 toxicity assays utilizing CMV/
Bsd (Invitrogen) in YZ-5 and EBS-7 cells, 150,000 cells were seeded
in T75 ﬂasks and transfected with 0.1 μg of CMV/Bsd and 2 μg of
LINE-1 expression/empty vector per plate. Selection media was
added 1 day later. For the ATM dominant negative experiments
100,000 HeLa cells were seeded per well of a 6 well plate a
transfected the next day with 1 μg of one of the two ATM
expression vectors in combination with 0.3 μg LINE-1 NeoR
(Moran et al., 1996) or NeoR per will in 6 well plates. Selection
media was added 1 day later.
500,000 HPV E6 expression HT1080 cells were seeded per T75
ﬂask and allowed to grow overnight. The cells were then trans-
fected with 3 μg LINE-1 Blast (Morrish et al., 2002). Selection
media was added the following day.
Colony Staining
Following applicable transfections and treatments, cells were
grown in selective media for 10–14 days. Following this growth
period, colonies were ﬁxed and stained for 30 min to 1 h with
crystal violet (0.2% crystal violet in 5% acetic acid and 2.5%
isopropanol).
DNA constructs
All HPV E6 constructs were cloned into the pLXSN vector
(Miller and Rosman, 1989) after being generated by PCR ampliﬁca-
tion from full length HPV DNA. The construction of the vectors has
been previously described. p300wt and p300S1834E vectors have
been previously described (Howie et al., 2011). The LINE-1 expres-
sion vector without a selectable cassette was JM101/L1.3 CEP no
tag (Moran et al., 1996) digested with SgrAI and then with ExoIII
timed to eliminate sequences associated with episomal replica-
tion. This DNA was then treated with Mung Bean nuclease and
ligated. All LINE-1 plasmids were kind gifts from John V. Moran
(University of Michigan Medical School, Ann Arbor, MI). The NeoR
plasmid used to control for toxicity variations is pIRES2-EGFP (BD
Biosciences Clontech, Palo Alto, CA). The BlastR expression plasmid
used for ATM +/- toxicity assays is pCMV/Bsd (Invitrogen, Carlsbad,
CA). pcDNA-FLAG-ATMwt and kinase defective (ATMkd) were gifts
of M. B. Kastan (Duke University, Durham, NC). To employ these
constructs with the LINE-1 NeoR plasmids, the NeoR promorter
and ORF was deleted from the ATM constructs with a NaeI digest
and subsequent religation.
A previously described fully synthetic version of LINE-1-RP
ORFs was constructed in the pBud4CE.1 vector (Invitrogen) and
used for COMET analysis (Gasior et al., 2006). The synthetic LINE-1
ORF2 from this LINE-1 was separately cloned into the pBud4CE.1
vector and used to measure LINE-1 related toxicity in HT1080 cells
expressing HPV E6 proteins.
Cellular proliferation assay
We used a previously described methods for measuring cellular
proliferation (Wallace et al., 2008). Brieﬂy, 500,000 HPV E6
expressing HT1080 cells were transfected with either LINE-1
ORF2 or an empty vector. Selection media was added the following
day and maintained for 3 days. On the third day, cells wereharvested by Trypsin/EDTA treatment and a hemocytometer was
used to compare the ability to cells to proliferate following
transfection with either empty vector (pbud) or LINE-1 ORF2.
Neutral COMET assay
A neutral comet assay was performed by using the COMET
Assay rReagent Kit for Single Cell Gel Electrophoresis (Trevigen,
Gaithersburg, MD) following the manufacturer's instructions. Cells
were mixed with low melting agarose (COMET LMAgarose, Trevi-
gen) and embedded on a slide (COMETSlide, Trevigen). Slides were
incubated in cold lysis solution (Trevigen) for 30 min at 4 1C. Slides
were then rinsed in 1 TBE and placed ﬂat onto a gel tray
submerged in 1 TBE buffer. Cells were electrophoresed in a
horizontal gel apparatus (Bio-Rad, Hercules, CA) at 1 V/cm for
15 min at room temperature. Slides were air-dried overnight and
DNA stained with SYBR Green I (Trevigen). Cells were analyzed
using an epiﬂuorescence microscope (Nikon, Melville, NY). Digital
images were acquired with a SensiCam QE digital camera (Cooke
Corporation, Romulus, MI). Tail moments were quantiﬁed for at
least 60 random cells per sample by using COMET Assay IV
(Perceptive Instruments, United Kingdom) COMET scoring soft-
ware. Tail moment is deﬁned as the ratio of DNA in the COMET tail
to total DNA.
Rt-PCR
RNA was isolated with Trizol reagent (Invitrogen). Brieﬂy, 1 ml
of Trizol was added to each 10-cm plate, cells were incubated for
5 min, and 200 ml of chloroform was added. The aqueous phase
was transferred and mixed with an equal volume of isopropanol,
incubated for 10 min, and pelleted at 12,000 rpm for 10 min at
4 1C. After being washed with 75% ethanol, the samples were again
pelleted at 9000 rpm for 5 min and resuspended in in RNase free
water. 1 μg of total RNA was reverse transcribed to generate cDNA,
using the iScript cDNA synthesis kit (BioRad, Hercules, CA). As a
negative control, parallel samples were run without reverse
transcriptase. Using previously described primers (Howie et al.,
2011), semi-quantitative PCR ampliﬁcation was then performed to
identify 100 bp amplicons with E6 and 36B4 primers as previously
described (Howie et al., 2011).
DNA damage
Cells were seeded and grown overnight. The following morn-
ing, cells were washed once with PBS and then irradiated through
a thin ﬁlm of PBS for one minute, exposing them to 10 mJ/cm2 UVB
irradiation. Fresh media was then added to the cells. The UVB
source is a parallel bank of two FS20t12/UVB bulbs (Solarc
Systems, Inc., Barrie, ON, Canada) with an output range of 290 to
320 nm. The UVB output is measured with an IL1400A radiometer
coupled with the SEL240/UVB-1/TD UVB detector (International
Light, Peabody, MA).
Immunoblotting
Whole cell extracts were prepared by mechanically detaching
cells in cold PBS and resuspending in WE16th lysis buffer (50 nM
Tris–HCl at pH 7.5, 250 mM NaCl, 5 mM EDTA, 1% NP-40, 0.1%
sodium dodecul sulfate, 20% glycerol, 80 mM β-glycero-phosphate,
50 mM sodium ﬂuoride, 1 mM sodium orthovanadate, and a
COMPLETE protease inhibitor tablet (Roche, Alameda, CA). Lysates
were then sonicated and clariﬁed by centrifugation. The DC
protein assay (Biorad, Hercules, CA) was used to determine protein
concentrations. Equal amounts of protein lysates (15–30 μg) were
electrophoresed on SDS-polyacrylamide gels and transferred to
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branes were then exposed to primary antibodies against p53
(Pantropic DO-1, Calbiochem, San Diego, CA), ATM (Cell Signaling,
Danvers, MA), nucleolin (Santa Cruz Biotechnology, Santa Cruz,
CA), β-actin (Santa Cruz Biotechnology), and phospho-chk2
(Thr68) (Cell Signaling, Danvers, MA). After exposure to the
corresponding HRP-conjugated secondary antibody (Cell Signal-
ing), cells were visualized using lumilite HRP substrate (Thermo
Fisher Scientiﬁc, Rockford, IL).
Statistical analysis
Unless otherwise noted, statistical signiﬁcance was determined
by paired student T test and conﬁrmed when appropriate by two
way ANOVA with Bonferroni correction. Only p values less than or
equal to 0.05 were reported as signiﬁcant.Acknowledgments
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